What Happens If Prostate Cancer Spreads to the Bones? Treatment, Prognosis, and Next Steps

TL;DR

• Prostate cancer commonly spreads to bones such as the spine, pelvis, hips, and ribs when it becomes metastatic. Bone metastases can cause pain, fractures, and, more rarely, spinal cord compression.
• Treatment usually addresses both the cancer throughout the body and problems caused by individual bone metastases.
• Androgen deprivation therapy is commonly part of systemic treatment, while additional medicines, chemotherapy, radiotherapy, bone-protective treatments, or radiopharmaceuticals may be used depending on the disease situation.
• A stable or falling PSA can be encouraging, but PSA alone does not provide a complete picture of whether metastatic prostate cancer is stable.
• New weakness or numbness in the legs, difficulty walking, or new bladder or bowel problems alongside back pain can indicate spinal cord compression and require urgent medical assessment.

What does it mean when prostate cancer spreads to the bones?

Bone metastases mean prostate cancer cells have travelled from the prostate and formed tumors within bone.

This is called metastatic prostate cancer, or stage IV disease when distant spread is present. The bones are among the most common places prostate cancer spreads, frequently affecting the spine, pelvis, hips, and ribs.

mama health's patient conversations reflect this clinical pattern — people often describe the problem first through persistent back, hip, or pelvic pain, rather than through the phrase "bone metastases." \[7\] Some bone metastases cause no symptoms and are detected on imaging; others cause pain or weaken the affected bone.

Importantly, prostate cancer in a bone is still prostate cancer. It is not bone cancer — the cells originated in the prostate. For more background, see mama health's guide to where prostate cancer spreads first.

What does bone metastasis pain feel like?

Bone metastases can cause persistent or worsening pain, often in the back, pelvis, hips, or ribs, although pain has many possible causes.

European guidance identifies pain as an important possible symptom of prostate cancer bone metastases. In patient experiences shared with mama health, bone pain often becomes the most tangible part of metastatic disease — people describe pain that remains present rather than disappearing like a minor strain or injury. \[7\]

However, pain alone cannot tell you whether prostate cancer has spread. Back and hip pain are common for many non-cancer reasons, and a healthcare professional can assess unexplained, persistent, or changing pain in the context of someone's cancer history and other findings.

What problems can prostate cancer in the bones cause?

Bone metastases can cause pain and may weaken bones enough to increase the risk of fractures or other skeletal complications.

Possible complications include:

• persistent bone pain
• pathological fractures, meaning a bone breaks because it has been weakened
• vertebral collapse
• the need for radiotherapy or surgery to a painful or weakened bone
• spinal cord compression when disease in the spine places pressure on the spinal cord

These are often collectively called skeletal-related events. Bone-protective medicines may be used in some metastatic settings to reduce or delay these complications.

When is bone pain an emergency?

Back pain accompanied by new neurological symptoms can indicate spinal cord compression and needs urgent medical attention.

Spinal cord compression happens when cancer in or near the spine places pressure on the spinal cord. Warning signs can include:

• new weakness in one or both legs, or numbness/altered sensation
• difficulty standing or walking
• new problems controlling the bladder or bowel
• severe or rapidly worsening back pain

The EAU describes impending spinal cord compression as an emergency requiring rapid assessment. Anyone experiencing these symptoms should seek urgent medical assessment rather than waiting for a routine cancer appointment.

How are prostate cancer bone metastases treated?

Treatment usually combines therapy aimed at prostate cancer throughout the body with treatments designed to protect bones, relieve symptoms, or address individual metastases.

This distinction can be difficult to see when several treatments happen at once. Patient conversations analyzed by mama health reflect that confusion — people can often name the therapies they receive (hormone therapy, chemotherapy, an infusion "for the bones," radiotherapy) but may be less clear about why those treatments sit alongside one another. \[7\]

A useful way to understand the plan is to separate it by purpose:

Systemic treatment targets prostate cancer cells throughout the body. Depending on whether the disease is hormone-sensitive or castration-resistant and on previous treatments, this may involve androgen deprivation therapy, androgen-receptor pathway medicines, chemotherapy such as docetaxel, targeted treatments for selected cancers, or radioligand therapy in selected patients. Modern treatment generally uses combinations rather than relying on ADT alone for many patients fit for intensified treatment.

Treatment directed at a particular bone metastasis — radiotherapy may be used to reduce pain or address a problematic lesion.

Bone-protective treatment — medicines such as zoledronic acid or denosumab may be used in selected circumstances to reduce skeletal complications.

Symptom and supportive care — pain management, physical support, rehabilitation, and management of treatment side effects.

This layered approach explains why two medicines given at the same time may be doing very different jobs.

Why is hormone therapy used when prostate cancer has spread to bone?

Hormone therapy reduces androgen signaling that prostate cancer commonly depends on for growth.

Androgen deprivation therapy (ADT) lowers testosterone or prevents its production, and is a central part of treatment for metastatic prostate cancer. Current strategies frequently combine ADT with additional systemic therapies rather than using ADT alone — which combination is discussed depends on whether the cancer is newly metastatic, how much disease is present, previous treatment, general health, and the cancer's biological characteristics.

ADT is treating the prostate cancer, not specifically repairing bone damage — a distinction that matters once bone-protective medicines are added.

What are zoledronic acid and denosumab used for?

Zoledronic acid and denosumab can help reduce complications caused by weakened bones in appropriate patients, but they do not replace treatment directed at the prostate cancer itself.

Zoledronic acid is a bisphosphonate. Denosumab is an antibody that blocks RANKL, a protein involved in the activity of cells that break down bone. In metastatic castration-resistant prostate cancer with bone metastases, these medicines can delay problems such as fractures, spinal cord compression, or the need for radiotherapy or surgery to bone. EAU evidence summaries note that denosumab delayed skeletal-related events compared with zoledronic acid in a major randomized study, though this didn't translate into an overall-survival benefit.

This helps explain a phrase patients commonly hear: "This one is for your bones." That doesn't necessarily mean it treats the cancer the way hormone therapy or chemotherapy does — its purpose may instead be to reduce the risk of complications involving bone.

Are bone-protective drugs the same as osteoporosis treatment?

The same medicines may be used in different doses or settings for cancer-related bone complications and for bone loss caused by long-term hormone therapy.

ADT itself can reduce bone density and increase fracture risk, so clinicians may think about bone health for two separate reasons: cancer has spread into the bones, or cancer treatment may weaken otherwise unaffected bone over time. The treatment purpose, dose, and schedule can differ accordingly.

Zoledronic acid can affect kidney function, and both zoledronic acid and denosumab can rarely cause osteonecrosis of the jaw, so dental health and other risk factors may be discussed before or during treatment.

How does radiotherapy help with painful bone metastases?

Radiotherapy can target a specific bone metastasis to reduce pain and manage local complications.

It's different from systemic therapy: ADT, chemotherapy, and many other medicines circulate through the body, while external-beam radiotherapy focuses on a particular area. EAU guidance describes external-beam radiotherapy as effective for painful bone metastases, including a single treatment fraction in appropriate situations.

Radiotherapy may be discussed when one particular lesion is causing significant pain even while systemic treatment continues — which explains why someone may receive chemotherapy or hormone therapy and radiotherapy at roughly the same stage of care: they're addressing different problems.

What is radium-223, or Xofigo?

Radium-223 is a bone-targeting radioactive treatment used for specific forms of metastatic castration-resistant prostate cancer involving symptomatic bone metastases.

Radium-223 behaves somewhat like calcium and accumulates in areas of increased bone turnover around metastases, emitting short-range alpha radiation there. In the European Union, Xofigo is authorized for selected adults with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastases, with specific restrictions that need to be considered alongside previous treatment and other available options.

Radium-223 is not simply "another chemotherapy" — it's a radiopharmaceutical with a particular role in selected bone-predominant prostate cancer.

What is Pluvicto and how is it different from radium-223?

Pluvicto is a radioligand therapy that targets PSMA-positive prostate cancer cells, whereas radium-223 preferentially targets areas of active bone turnover around bone metastases.

Pluvicto contains lutetium-177 linked to a molecule that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells — a different mechanism from radium-223. As of August 2026, the European Medicines Agency describes Pluvicto as an option for adults with progressive PSMA-positive metastatic castration-resistant prostate cancer in an authorized treatment setting, with eligibility depending on the cancer's characteristics and previous treatments.

This addresses a common information gap: radium-223 and lutetium-PSMA may both involve radiation, but they target the disease in different ways and are not interchangeable treatments.

Is chemotherapy always needed when prostate cancer spreads to the bones?

No. Bone metastases do not automatically mean chemotherapy is the immediate or only treatment option.

Chemotherapy such as docetaxel is one systemic treatment used in metastatic prostate cancer, but sequencing depends on the disease setting — other options include ADT combined with androgen-receptor pathway treatments, chemotherapy-containing combinations, targeted therapies in selected molecular subgroups, and later-line treatments such as radioligand therapy in appropriate patients.

Patient experiences shared with mama health show that chemotherapy often carries particular emotional weight — some people fear being told it's inevitably "what comes next." \[7\] A more useful question is often "Why is this treatment being considered at this point in my disease?" — which can open a discussion about the goal of treatment, alternatives, expected benefits, and side effects.

How do doctors know whether treatment for bone metastases is working?

Doctors usually combine symptoms, PSA, imaging, examination, and other clinical findings rather than relying on PSA alone.

This matters because patients frequently use PSA as shorthand for the entire cancer situation. A falling or stable PSA may feel reassuring and can provide useful information in many prostate cancers — but PSA doesn't always move in parallel with radiographic progression. EAU follow-up guidance notes that metastatic progression can sometimes occur without a corresponding PSA rise.

That means stable PSA does not always equal stable disease, and a PSA rise doesn't by itself explain everything happening. Clinical teams may also consider new or changing symptoms, imaging findings, treatment response, blood tests, physical function, and the location and extent of metastatic disease.

What side effects can treatment for metastatic prostate cancer cause?

Side effects depend on the treatments being used, and for many people they affect everyday life as much as the cancer itself.

Patient experiences shared with mama health repeatedly focus on treatment burden — commonly discussed concerns include fatigue, hot flashes, joint or muscle discomfort, sexual changes, urinary problems, skin changes, hair loss with some chemotherapy regimens, and reduced physical stamina. \[7\] Different therapies have different side-effect profiles, so these effects shouldn't be treated as inevitable for everyone.

Asking "Will it work?" is only half the treatment conversation — people also want to know "What might everyday life be like while I'm taking it?", including practical questions about walking, work, sleep, driving, sexual function, family responsibilities, exercise, and fatigue.

What is the prognosis when prostate cancer spreads to the bones?

Bone metastases mean prostate cancer is metastatic, but they do not provide a precise prediction of how long one person will live.

Metastatic prostate cancer is generally not considered curable with current treatments, but modern therapies can control disease for varying periods of time. Outlook can depend on whether the cancer remains hormone-sensitive or has become castration-resistant, how extensive the metastases are, whether cancer is confined predominantly to bone or has spread to organs, response to systemic treatment, cancer genetics, general health, and available future treatments.

Bone metastases are therefore one part of the prognosis — not a personal countdown. Patient experiences suggest people often approach prognosis indirectly — rather than asking "How long do I have?", they may ask whether their PSA is stable or the current treatment is still working. \[7\] Behind those questions is often the same concern: "Do I still have time?" A healthcare professional can provide more context by explaining what stability means across PSA, scans, symptoms, and overall disease behavior.

Does bone metastasis mean the cancer is immediately terminal?

No. Bone metastases indicate advanced prostate cancer, but they do not mean death is necessarily imminent.

People can have very different courses after bone metastases are identified — some respond to treatment for substantial periods, while others progress more quickly. Terms such as metastatic, hormone-sensitive, and castration-resistant provide more useful information than assuming all stage IV prostate cancer behaves the same way. For a wider discussion, see mama health's guide to prostate cancer stages.

What can happen if one treatment stops working?

If metastatic prostate cancer progresses, another treatment may sometimes be discussed depending on previous therapy, cancer characteristics, symptoms, and overall health.

There is not one universal sequence everyone follows. A future treatment could come from a different category — another androgen-receptor-directed strategy, chemotherapy, a PARP-targeted approach in cancers with relevant genetic alterations, radium-223 in an appropriate bone-predominant setting, lutetium-PSMA for eligible PSMA-positive disease, local radiotherapy for specific painful sites, or symptom-directed and supportive treatments.

Current EAU guidance emphasizes treatment selection according to previous treatment, disease characteristics, performance status, symptoms, and molecular findings — which is why "What comes after docetaxel?" doesn't have one answer that applies to everyone.

Why can treatment decisions feel confusing?

Metastatic prostate cancer often requires several treatments with different purposes, making the sequence difficult to understand without a clear explanation.

mama health's patient conversations show two different experiences. \[7\] Some people receiving care through multidisciplinary teams describe feeling involved in discussions and understanding why one treatment comes before another. Others describe receiving a plan without understanding why that particular therapy was chosen or what alternatives had been considered.

Patients repeatedly express a need for clearer explanations of why this treatment is being used now, information about other options, access to specialist nursing support, help with the practical impact of treatment, and better pain support during transitions between therapies. These are reasonable areas to bring into an oncology appointment.

What questions could you ask about treatment for bone metastases?

You could consider asking:

1. Is this treatment targeting the prostate cancer itself, protecting my bones, relieving pain, or more than one of these?
2. Why is this treatment being considered now, and what tells us whether it's working?
3. Apart from PSA, what findings will you use to assess the cancer?
4. What side effects could affect my daily activities?
5. What should I do if my bone pain becomes worse, and is there a particular fracture risk from any of my bone metastases?
6. Would radiotherapy be relevant for a painful lesion, and what is the role of zoledronic acid or denosumab in my situation?
7. What other treatment categories might be discussed if this one eventually stops working?
8. Who should I contact between appointments if pain or other symptoms change?

These are preparation prompts rather than treatment recommendations.

How can bone pain be managed while cancer treatment is changing?

Bone pain deserves its own management plan and does not always need to wait for the next systemic cancer treatment to begin.

Depending on the cause and severity, a clinical team may discuss pain medicines, radiotherapy, procedures for unstable or fractured bones, or other supportive approaches. Patient experiences suggest that pain can feel particularly under-addressed during transitions between therapies. \[7\]

Persistent or changing pain should be communicated to the healthcare team rather than treated only as a marker of whether a cancer medicine is working. New severe back pain with weakness, numbness, walking difficulty, or bladder or bowel changes requires urgent assessment because of the possibility of spinal cord compression.

What should you remember if prostate cancer has spread to the bones?

Bone metastases make prostate cancer an advanced disease, but treatment involves much more than treating the bones alone.

A useful way to understand the plan is to ask what each part is trying to accomplish: systemic treatment addresses prostate cancer throughout the body, bone-protective medicines can reduce certain skeletal complications, radiotherapy can target painful or problematic areas, radiopharmaceuticals and radioligand treatments use radiation in specialized ways for selected situations, and supportive care addresses pain, side effects, function, and quality of life. Monitoring usually involves more than PSA alone.

For many patients, knowing why each treatment is there can be as important as remembering its name.

Disclaimer: This content is informational. mama health offers information and support and does not replace a doctor.